PDF(Pubmed)
Abstract：
Background/Objectives: Acquired brain injury (ABI) is a major cause of global disability. Many ABI patients exhibit oculomotor dysfunctions that impact their daily life and rehabilitation outcomes. Current clinical tools for oculomotor function (OMF) assessment are limited in their usability. In this proof-of-principle study, we aimed to develop an efficient tool for OMF screening and to assess the feasibility, acceptability, and relevance in a small sample of ABI and control participants. Methods: We created the Rehabilitation Oculomotor Screening Evaluation (ROSE) by reviewing existing OMF assessments. ROSE was pilot-tested on ABI patients (n = 10) and age-matched controls (n = 10). Data regarding the characteristics of the assessment, such as the duration, level of participant comprehension, and participant experience were also collected. Results: ROSE takes <20 min (x¯ = 12.5), is easy to complete (agreement x¯ = 4.6/5), and is well-accepted (x¯ = 4.8/5). Patients scored higher in all subtests and total score (x¯ = 34.8 for ABI vs. 8.9 for controls). Most subtests did not provoke any symptoms, especially for controls. There were no significant between-group differences in symptom provocation. This proof-of-principle study shows that ROSE is feasible, acceptable, and relevant for adult ABI patients. Conclusions: ROSE needs further evaluation for reliability testing and validation in larger samples and diverse neurological conditions. Establishing norms for various ages, sexes, and populations should be considered for the deployment of ROSE as an OMF clinical tool.
摘要：
背景/目的：获得性脑损伤（ABI）是全球残疾的主要原因。许多ABI患者表现出影响其日常生活和康复结果的动眼功能障碍。当前用于动眼功能(OMF)评估的临床工具在其可用性方面受到限制。在这项原理证明研究中，我们的目标是开发一种有效的OMF筛查工具，并评估其可行性，可接受性,以及在ABI和对照参与者的小样本中的相关性。方法：我们通过回顾现有的OMF评估创建了康复眼动筛查评估（ROSE）。对ABI患者（n=10）和年龄匹配的对照（n=10）进行了ROSE的初步测试。有关评估特征的数据，比如持续时间，参与者的理解水平，还收集了参与者的经验。结果：ROSE需要<20分钟（x'=12.5），很容易完成(协议x并=4.6/5)，并且是公认的（x'=4.8/5）。患者在所有子测试和总分中均得分较高（ABI与ABI的x'=34.88.9用于控件)。大多数子测试没有引起任何症状，尤其是控制。症状激发的组间差异无统计学意义。这项原理验证研究表明，ROSE是可行的，可接受,与成人ABI患者相关。结论：ROSE需要进一步评估，以便在更大的样本和不同的神经系统疾病中进行可靠性测试和验证。建立各种年龄的规范，性别,应考虑将ROSE部署为OMF临床工具。
